NCT00074243已完成1 期
A Phase I Trial Of CC-8490 For The Treatment Of Patients With Recurrent/Refractory High-Grade Gliomas
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as CC-8490, work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of CC-8490 in treating patients who have recurrent or refractory high-grade gliomas.
详细描述
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of CC-8490 in patients with recurrent or refractory high-grade gliomas.
- Determine, preliminarily, the toxic effects of this drug in these patients.
- Determine the pharmacokinetics of this drug in these patients.
Secondary
- Determine, preliminarily, the potential anti-glioma activity of this drug in these patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed supratentorial malignant glioma, including any of the following:
- •Glioblastoma multiforme
- •Gliosarcoma
- •Anaplastic astrocytoma
- •Anaplastic oligodendroglioma
- •Anaplastic mixed oligoastrocytoma
- •Malignant glioma/astrocytoma not otherwise specified OR
- •Clinical and radiographic diagnosis of progressive low-grade glioma
- •Radiographically diagnosed infiltrating brain stem gliomas not amenable to biopsy allowed
- •Recurrent or progressive disease as determined by 1 of the following:
- •CT scan or MRI within the past 21 days
- •Biopsy within the past 12 weeks
- •Failed prior radiotherapy
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Karnofsky 60-100%
- •Life expectancy
- •More than 8 weeks
- •Hematopoietic
- •Granulocyte count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3 (transfusion independent)
- •Hemoglobin at least 8 g/dL (transfusion allowed)
- •Bilirubin no greater than 1.5 mg/dL
- •AST and ALT no greater than 2 times upper limit of normal
- •No significant active hepatic disease that would preclude study participation
- •Creatinine no greater than 1.5 mg/dL OR
- •Creatinine clearance at least 60 mL/min
- •No significant active renal disease that would preclude study participation
- •Cardiovascular
- •No significant active cardiac disease that would preclude study participation
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 2 months after study participation
- •No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- •No significant active psychiatric disease that would preclude study participation
- •No other condition or laboratory abnormality that would preclude study participation
- •Able to swallow capsules whole
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •At least 2 weeks since prior interferon
- •No concurrent immunotherapy
- •Chemotherapy
- •At least 2 weeks since prior vincristine
- •At least 3 weeks since prior procarbazine
- •At least 4 weeks since prior temozolomide or carboplatin
- •At least 6 weeks since prior nitrosoureas
- •No other concurrent anticancer chemotherapy
- •Endocrine therapy
- 另有 11 项未显示
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00005026Gynecologic Oncology Group
终止
1 期
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver ImpairmentChronic Myeloproliferative DisordersMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesLymphomaLeukemiaNCT00004239Alliance for Clinical Trials in Oncology10
已完成
2 期
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver CancerLiver CancerNCT00095992NCIC Clinical Trials Group15
Unknown
2 期
CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue SarcomaSarcomaNCT00017446Herbert Irving Comprehensive Cancer Center
终止
1 期
Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00003378Gynecologic Oncology Group45